What is CAMP4 Therapeutics?
CAMP4 Therapeutics is at the forefront of drug discovery and development, employing a novel Gene Circuitry Platform designed to precisely modulate gene expression. This innovative approach allows the company to systematically identify and develop druggable targets for a wide range of diseases, particularly those considered undruggable. By creating tissue-specific Gene Circuitry Maps, CAMP4 deciphers the complex transcriptional machinery and signaling networks that govern gene expression, uncovering numerous therapeutic opportunities. The company's mission is to accelerate the discovery of new treatments across all therapeutic areas, aiming to make a treatment possible for every disease.
How much funding has CAMP4 Therapeutics raised?
CAMP4 Therapeutics has raised a total of $175M across 3 funding rounds:
Series A
$30M
Other Financing Round
$45M
Series B
$100M
Series A (2018): $30M with participation from The Kraft Group, Andreessen Horowitz, and Polaris Partners
Other Financing Round (2021): $45M led by Polaris Partners, Andreessen Horowitz, The Kraft Group, 5AM Ventures, and Northpond Ventures
Series B (2022): $100M supported by Polaris Partners, Northpond Ventures, Enavate Sciences, Andreessen Horowitz, The Kraft Group, 5AM Ventures, and Gaingels
Key Investors in CAMP4 Therapeutics
The Kraft Group
The Kraft Group is a diversified holding company with interests in manufacturing, distribution, sports and entertainment, real estate, and private equity. Their investment in CAMP4 Therapeutics suggests a strategic interest in innovative ventures with significant growth potential.
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm known for investing in both early-stage and established technology companies. Their involvement indicates confidence in CAMP4's disruptive technology and market strategy within the biotech landscape.
Polaris Partners
Polaris Partners is a venture capital firm specializing in the biotech and healthcare sectors, focusing on backing transformational companies. Their continued investment in CAMP4 Therapeutics highlights their commitment to advancing innovative solutions in life sciences.
What's next for CAMP4 Therapeutics?
The recent major strategic investment signifies a pivotal moment for CAMP4 Therapeutics, positioning it for accelerated scaling and further platform development. This influx of capital is expected to fuel the expansion of its research and development initiatives, enabling the company to deepen its understanding of transcriptional machinery and signaling pathways. With a clear focus on addressing undruggable diseases, CAMP4 is poised to translate its platform's potential into tangible therapeutic solutions, marking a significant advancement in the biotechnology sector.
See full CAMP4 Therapeutics company page
